verosudil
Small moleculeexperimental
Clinical trial activity
12 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
11
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2009 (NCT00902200)
Timeline
Indications
Mechanism of action
- Rho-associated protein kinaseINHIBITOR
Rho-associated protein kinase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)C(C(=O)Nc1ccc2c(=O)[nH]ccc2c1)c1ccsc1- Mol. weight
- 327.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545065 ↗
Also known as
- ar-12286
- ar-12286
- ar-12286
- verosudil
- verosudil
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02174991 | Phase 2 | Jun 1, 2014 | New York Glaucoma Research Institute |
| NCT02173223 | Phase 2 | Jun 1, 2014 | New York Glaucoma Research Institute |
| NCT02152774 | Phase 2 | May 1, 2014 | New York Glaucoma Research Institute |
| NCT01936389 | Phase 2 | Sep 1, 2013 | Glaucoma Associates of New York |
| NCT01789736 | Phase 2 | Feb 1, 2013 | Aerie Pharmaceuticals |
| NCT01699464 | Phase 2 | Oct 1, 2012 | Aerie Pharmaceuticals |
| NCT01474135 | Phase 2 | Dec 1, 2011 | Aerie Pharmaceuticals |
| NCT01330979 | Phase 2 | May 1, 2011 | Aerie Pharmaceuticals |
| NCT01302249 | Phase 2 | Feb 1, 2011 | Aerie Pharmaceuticals |
| NCT01250197 | Phase 1 | Nov 1, 2010 | Aerie Pharmaceuticals |
| NCT01060579 | Phase 2 | Feb 1, 2010 | Aerie Pharmaceuticals |
| NCT00902200 | Phase 2 | May 1, 2009 | Aerie Pharmaceuticals |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aerie Pharmaceuticals | For profit | 8 | 8 | 2 | 2009 |
| New York Glaucoma Research Institute | Academic/Hospital | 3 | 3 | 1 | 2014 |
| Glaucoma Associates of New York | Academic/Hospital | 1 | 1 | 1 | 2013 |
3 organizations
Page 1 / 1